TY - JOUR
T1 - Comparative Effectiveness of Baricitinib Versus Tocilizumab in Hospitalized Patients With COVID-19
T2 - A Retrospective Cohort Study of the National Covid Collaborative
AU - National COVID Cohort Collaborative (N3C) Consortium
AU - Patanwala, Asad E.
AU - Xiao, Xuya
AU - Hills, Thomas E.
AU - Higgins, Alisa M.
AU - McArthur, Colin J.
AU - Caleb Alexander, G.
AU - Mehta, Hemalkumar B.
AU - Wilcox, Adam B.
AU - Lee, Adam M.
AU - Graves, Alexis
AU - Anzalone, Alfred
AU - Manna, Amin
AU - Saha, Amit
AU - Olex, Amy
AU - Zhou, Andrea
AU - Williams, Andrew E.
AU - Southerland, Andrew
AU - Girvin, Andrew T.
AU - Walden, Anita
AU - Sharathkumar, Anjali A.
AU - Amor, Benjamin
AU - Bates, Benjamin
AU - Hendricks, Brian
AU - Patel, Brijesh
AU - Alexander, Caleb
AU - Bramante, Carolyn
AU - Ward-Caviness, Cavin
AU - Madlock-Brown, Charisse
AU - Suver, Christine
AU - Chute, Christopher
AU - Dillon, Christopher
AU - Wu, Chunlei
AU - Schmitt, Clare
AU - Takemoto, Cliff
AU - Housman, Dan
AU - Gabriel, Davera
AU - Eichmann, David A.
AU - Mazzotti, Diego
AU - Brown, Don
AU - Boudreau, Eilis
AU - Hill, Elaine
AU - Zampino, Elizabeth
AU - Carlson Marti, Emily
AU - Pfaff, Emily R.
AU - French, Evan
AU - Koraishy, Farrukh M.
AU - Mariona, Federico
AU - Prior, Fred
AU - Sokos, George
AU - Martin, Greg
AU - Lehmann, Harold
AU - Spratt, Heidi
AU - Mehta, Hemalkumar
AU - Liu, Hongfang
AU - Sidky, Hythem
AU - Awori Hayanga, J. W.
AU - Pincavitch, Jami
AU - Clark, Jaylyn
AU - Harper, Jeremy Richard
AU - Islam, Jessica
AU - Ge, Jin
AU - Gagnier, Joel
AU - Saltz, Joel H.
AU - Saltz, Joel
AU - Loomba, Johanna
AU - Buse, John
AU - Mathew, Jomol
AU - Rutter, Joni L.
AU - McMurry, Julie A.
AU - Guinney, Justin
AU - Starren, Justin
AU - Crowley, Karen
AU - Bradwell, Katie Rebecca
AU - Walters, Kellie M.
AU - Wilkins, Ken
AU - Gersing, Kenneth R.
AU - Cato, Kenrick Dwain
AU - Murray, Kimberly
AU - Kostka, Kristin
AU - Northington, Lavance
AU - Pyles, Lee Allan
AU - Misquitta, Leonie
AU - Cottrell, Lesley
AU - Portilla, Lili
AU - Deacy, Mariam
AU - Bissell, Mark M.
AU - Clark, Marshall
AU - Emmett, Mary
AU - Saltz, Mary Morrison
AU - Palchuk, Matvey B.
AU - Haendel, Melissa A.
AU - Adams, Meredith
AU - Temple-O'Connor, Meredith
AU - Kurilla, Michael G.
AU - Morris, Michele
AU - Qureshi, Nabeel
AU - Safdar, Nasia
AU - Garbarini, Nicole
AU - Sharafeldin, Noha
AU - Sadan, Ofer
AU - Francis, Patricia A.
AU - Burgoon, Penny Wung
AU - Robinson, Peter
AU - Payne, Philip R.O.
AU - Fuentes, Rafael
AU - Jawa, Randeep
AU - Erwin-Cohen, Rebecca
AU - Patel, Rena
AU - Moffitt, Richard A.
AU - Zhu, Richard L.
AU - Kamaleswaran, Rishi
AU - Hurley, Robert
AU - Miller, Robert T.
AU - Pyarajan, Saiju
AU - Michael, Sam G.
AU - Bozzette, Samuel
AU - Mallipattu, Sandeep
AU - Vedula, Satyanarayana
AU - Chapman, Scott
AU - O'Neil, Shawn T.
AU - Setoguchi, Soko
AU - Hong, Stephanie S.
AU - Johnson, Steve
AU - Bennett, Tellen D.
AU - Callahan, Tiffany
AU - Topaloglu, Umit
AU - Sheikh, Usman
AU - Gordon, Valery
AU - Subbian, Vignesh
AU - Kibbe, Warren A.
AU - Hernandez, Wenndy
AU - Beasley, Will
AU - Cooper, Will
AU - Hillegass, William
AU - Zhang, Xiaohan Tanner
N1 - Publisher Copyright:
Copyright © 2024 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
PY - 2025/1/1
Y1 - 2025/1/1
N2 - OBJECTIVES: COVID-19 treatment guidelines recommend baricitinib or tocilizumab for the management of hospitalized patients with COVID-19. We compared the effectiveness of baricitinib vs. tocilizumab on mortality and clinical outcomes among hospitalized patients with COVID-19. DESIGN: Multicenter, retrospective, propensity-weighted cohort study using a target trial emulation approach. SETTING: The National COVID Cohort Collaborative (N3C), which is the largest electronic health records data on COVID-19 in the United States. The setting included 75 hospitals. PATIENTS: Adults who were hospitalized for COVID-19. INTERVENTIONS: Newly initiated on baricitinib or tocilizumab. MEASUREMENTS AND MAIN RESULTS: Our primary outcome was 28-day mortality. We used propensity scores with inverse probability of treatment weights (IPTWs) to control bias and confounding while comparing treatments. Among 10,661 individuals included in the study, 6,229 (58.4%) received baricitinib and 4,432 (41.6%) tocilizumab. Overall, the mean age of the cohort was 60.0±15.1 years, 6429 (60.3%) were male, and 19.2% received invasive mechanical ventilation. After IPTW adjustment, baricitinib use was associated with lower 28-day mortality (odds ratio [OR], 0.91; 95% CI, 0.85–0.98) and hospital (OR, 0.88; 95% CI, 0.82–0.94) mortality compared with tocilizumab. Baricitinib was also associated with shorter hospital length of stay (incident rate ratio, 0.92; 95% CI, 0.90–0.94) and lower rates of hospital-acquired infections (OR, 0.86; 95% CI, 0.75–0.99), although no difference in ICU length of stay was noted between the two groups. CONCLUSIONS: In this large, diverse cohort of U.S. hospitalized adults with COVID-19, baricitinib was associated with significantly lower 28-day mortality, hospital mortality, shorter hospital length of stay, and less hospital-acquired infections compared with tocilizumab.
AB - OBJECTIVES: COVID-19 treatment guidelines recommend baricitinib or tocilizumab for the management of hospitalized patients with COVID-19. We compared the effectiveness of baricitinib vs. tocilizumab on mortality and clinical outcomes among hospitalized patients with COVID-19. DESIGN: Multicenter, retrospective, propensity-weighted cohort study using a target trial emulation approach. SETTING: The National COVID Cohort Collaborative (N3C), which is the largest electronic health records data on COVID-19 in the United States. The setting included 75 hospitals. PATIENTS: Adults who were hospitalized for COVID-19. INTERVENTIONS: Newly initiated on baricitinib or tocilizumab. MEASUREMENTS AND MAIN RESULTS: Our primary outcome was 28-day mortality. We used propensity scores with inverse probability of treatment weights (IPTWs) to control bias and confounding while comparing treatments. Among 10,661 individuals included in the study, 6,229 (58.4%) received baricitinib and 4,432 (41.6%) tocilizumab. Overall, the mean age of the cohort was 60.0±15.1 years, 6429 (60.3%) were male, and 19.2% received invasive mechanical ventilation. After IPTW adjustment, baricitinib use was associated with lower 28-day mortality (odds ratio [OR], 0.91; 95% CI, 0.85–0.98) and hospital (OR, 0.88; 95% CI, 0.82–0.94) mortality compared with tocilizumab. Baricitinib was also associated with shorter hospital length of stay (incident rate ratio, 0.92; 95% CI, 0.90–0.94) and lower rates of hospital-acquired infections (OR, 0.86; 95% CI, 0.75–0.99), although no difference in ICU length of stay was noted between the two groups. CONCLUSIONS: In this large, diverse cohort of U.S. hospitalized adults with COVID-19, baricitinib was associated with significantly lower 28-day mortality, hospital mortality, shorter hospital length of stay, and less hospital-acquired infections compared with tocilizumab.
KW - COVID-19
KW - Janus kinase inhibitors
KW - hospitalization
KW - interleukin-6
KW - mortality
KW - severe acute respiratory syndrome coronavirus 2
UR - http://www.scopus.com/inward/record.url?scp=85207146375&partnerID=8YFLogxK
U2 - 10.1097/CCM.0000000000006444
DO - 10.1097/CCM.0000000000006444
M3 - Article
C2 - 39365115
AN - SCOPUS:85207146375
SN - 0090-3493
VL - 53
SP - e29-e41
JO - Critical care medicine
JF - Critical care medicine
IS - 1
ER -